Dutch cancer biotech LAVA Therapeutics sets terms for $101 million US IPO

LAVA Therapeutics, a Dutch Phase 1/2a biotech developing gamma-delta T cell therapies for cancer, announced terms for its IPO on Thursday.

The Utrecht, Netherlands-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to $16. At the midRead More